SCHEDULE: Vanguard Group Reports 0% Stake in 4D Molecular Therapeutics
Beneficial Ownership Report Amendment
The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in 4D Molecular Therapeutics Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 1 to its Schedule 13G for 4D Molecular Therapeutics Inc. (CUSIP: 35104E100).
- The filing reports that The Vanguard Group now beneficially owns 0 shares, representing 0% of the Common Stock of 4D Molecular Therapeutics Inc.
- This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis), and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over those securities.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing. It reflects a change in reporting structure for The Vanguard Group, not a positive or negative development for 4D Molecular Therapeutics Inc.
Future Outlook
NA
Management Comments
- On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
- Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
Industry Context
StockSavvy.ai notes that this filing is an administrative update reflecting The Vanguard Group's internal reporting structure changes, rather than a change in investment thesis for 4D Molecular Therapeutics. Such realignments are common among large asset managers to comply with regulatory interpretations regarding beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 01/12/2026 | Internal realignment of The Vanguard Group, Inc. occurred, leading to disaggregated reporting of beneficial ownership. |
| 03/13/2026 | Date of event requiring the filing of this statement. |
| 03/26/2026 | Date the Schedule 13G/A was signed by The Vanguard Group. |
Keywords
4D Molecular Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.